These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 32346686

  • 1. Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China.
    Zhang Y, Wang Y.
    J Nutr Health Aging; 2020; 24(5):485-493. PubMed ID: 32346686
    [Abstract] [Full Text] [Related]

  • 2. The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study.
    Ma R, Wu M, Li Y, Wang J, Yang P, Chen Y, Wang W, Song J, Wang K.
    J Orthop Surg Res; 2021 Mar 17; 16(1):195. PubMed ID: 33731168
    [Abstract] [Full Text] [Related]

  • 3. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
    Gao C, Qiao J, Li SS, Yu WJ, He JW, Fu WZ, Zhang ZL.
    Osteoporos Int; 2017 Jan 17; 28(1):211-218. PubMed ID: 27468899
    [Abstract] [Full Text] [Related]

  • 4. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    Medicine (Baltimore); 2018 Aug 17; 97(31):e11694. PubMed ID: 30075569
    [Abstract] [Full Text] [Related]

  • 5. The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study.
    Zhao J, Xia W, Nie M, Zheng X, Wang Q, Wang X, Wang W, Ning Z, Huang W, Jiang Y, Li M, Wang O, Xing X, Sun Y, Luo L, He S, Yu W, Lin Q, Pei Y, Zhang F, Han Y, Tong Y, Che Y, Shen R, Hu Y, Zhou X, Xu L.
    Menopause; 2011 Nov 17; 18(11):1237-43. PubMed ID: 21747303
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W, Sun J, Zhou L, Li Y, Wu X.
    J Clin Pharm Ther; 2016 Oct 17; 41(5):519-23. PubMed ID: 27440710
    [Abstract] [Full Text] [Related]

  • 7. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS, Harsløf T, Langdahl B.
    Osteoporos Int; 2019 May 17; 30(5):995-1002. PubMed ID: 30656367
    [Abstract] [Full Text] [Related]

  • 8. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
    Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD.
    Bone; 2020 Sep 17; 138():115478. PubMed ID: 32534221
    [Abstract] [Full Text] [Related]

  • 9. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
    Sølling AS, Harsløf T, Langdahl B.
    J Bone Miner Res; 2021 Jul 17; 36(7):1245-1254. PubMed ID: 33813753
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T, e-ADVANCED Study Group.
    Osteoporos Int; 2015 Mar 17; 26(3):1193-202. PubMed ID: 25592133
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Yigu® versus Aclasta® in Chinese postmenopausal women with osteoporosis: a multicenter prospective study.
    Li M, Cheng Q, Huo YN, Chao AJ, He L, Xue QY, Xu J, Yan SG, Jin H, Zhang ZL, Lin JH, Jin XL, Xu YJ, Liu F, Xia WB.
    Arch Osteoporos; 2022 Jan 12; 17(1):14. PubMed ID: 35020038
    [Abstract] [Full Text] [Related]

  • 12. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
    Kharroubi A, Saba E, Smoom R, Bader K, Darwish H.
    Arch Osteoporos; 2017 Dec 12; 12(1):13. PubMed ID: 28124221
    [Abstract] [Full Text] [Related]

  • 13. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 12; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 14. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A.
    Bone; 2017 Oct 12; 103():209-215. PubMed ID: 28687496
    [Abstract] [Full Text] [Related]

  • 15. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
    Bourke S, Bolland MJ, Grey A, Horne AM, Wattie DJ, Wong S, Gamble GD, Reid IR.
    Osteoporos Int; 2013 Jan 12; 24(1):349-54. PubMed ID: 22893357
    [Abstract] [Full Text] [Related]

  • 16. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
    Olmos JM, Hernández JL, Llorca J, Nan D, Valero C, González-Macías J.
    J Clin Endocrinol Metab; 2012 Dec 12; 97(12):4491-7. PubMed ID: 23043189
    [Abstract] [Full Text] [Related]

  • 17. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
    Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, Yao X, Gu G, Hao Y, Li Z, Zhao Y, Li W, Yang J, Zhao X, Shi D, Fuerst T, Lu Y, Li H, Zhang X, Li C, Zhao J, Wu Q, Zhao SJ.
    Osteoporos Int; 2012 Apr 12; 23(4):1317-27. PubMed ID: 21505910
    [Abstract] [Full Text] [Related]

  • 18. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.
    Clin Ther; 2007 Sep 12; 29(9):1937-49. PubMed ID: 18035193
    [Abstract] [Full Text] [Related]

  • 19. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E.
    Osteoporos Int; 2012 Mar 12; 23(3):1171-6. PubMed ID: 21305266
    [Abstract] [Full Text] [Related]

  • 20. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
    Anastasilakis AD, Polyzos SA, Yavropoulou MP, Appelman-Dijkstra NM, Ntenti C, Mandanas S, Papatheodorou A, Makras P.
    Calcif Tissue Int; 2021 May 12; 108(5):587-594. PubMed ID: 33386953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.